Theranostics : the State of the Art New publication in the Journal of Nuclear Medicine We are pleased to share this new article,"Theranostics: The State of the Art", co-authored by our Head of Nuclear Medicine, Dr Vincent

Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions PART 2 Part 2 of "Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions" is now out in the The Journal of Nuclear Medicine - JNM.Building on Part

Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions PART 1 Part 1 of "Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions" is now out in the The Journal of Nuclear Medicine - JNM. This publication

Radiopharmaceutical supply chain structure: 7/7 Final Step – Delivery to the Hospital and Administration to the Patient The last mile: where the supply chain finally meets the patient   Most medicines wait for the patient. A radiopharmaceutical

Radiopharmaceutical supply chain structure: 6/7 Step 6 – Drug Manufacturing Manufacturing: the often-overlooked bottleneck   When discussing radiopharmaceutical supply chains, supply concerns are often reduced to radionuclide availability. While securing isotope production remains essential, manufacturing capabilities have

Radiopharmaceutical supply chain structure: 5/7 Step 5 – Radionuclide Processing 🌐 The processing integration : moving from standalone assets to coupled supply chainsRadionuclide processing plays a central role in the radiopharmaceutical supply chain, transforming raw irradiation output (irradiated

Radiopharmaceutical supply chain structure: 4/7 Step 4 – Target Irradiation🌐 The Irradiation challenge : How the industry is securing the next generation of radionuclides Moving from targetry to the actual irradiation stage of radionuclide production requires a careful

Radiopharmaceutical supply chain structure: 3/7 Step 3 – Target Manufacturing and Preparation 🧪Transitioning from isotopic enrichment to the physical preparation of materials introduces one of the most critical engineering constraints in the supply chain: targetry.Target design and

Radiopharmaceutical supply chain structure: 2/7 Step 2 – Isotope EnrichmentCreating materials for nuclear medicine is incredibly tough, and it all comes down to how "clean" the raw ingredients are. To illustrate that, let’s look at two contrasting

Radiopharmaceutical supply chain structure: 1/7 Step 1 - Source material acquisition: is raw material supply a real threat to nuclear medicine? Prior to the enrichment stage, the industry needs to secure various ores (Nickel, Tellurium, Yttrium, Zinc, etc.).

Typical chain structure for a radiopharmaceutical Over the next 7 weeks, we’ll take you inside each step of the radiopharmaceutical supply chain. Radiopharmaceuticals play a critical role in modern healthcare, from cancer diagnostics to targeted therapies. But

SNMMI 2026 – Let’s connect in Los Angeles ! We are attending the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Los Angeles !Vincent Brechin, Ph.D. is on site to discuss the latest developments